New AMR Paper Explains Our Life-or-Death Battle with Superbugs and What We Need to Do to Win

The silent pandemic of antimicrobial resistance (AMR) is an under-recognized global health crisis that threatens the foundations of modern medicine.

New York, NEW YORK (February 17, 2022)—The Global Coalition on Aging (GCOA) today released a startling new paper, Wonder Drugs vs. Superbugs: The 21st Century Battle to Save 10 Million Lives a Year, which clearly lays out the global threat posed by rising drug resistance, widely known as antimicrobial resistance or AMR, and accompanying lack of effective new drugs. The paper, perhaps the first of its kind, asks us to imagine a world in which commonly used medicines no longer protect us from disease and suggests four steps for leaders in government, business, and across society to help avert this crisis. The paper was released alongside a series of regional infographics and Calls to Action on AMR for the United States, the European Union, and Japan. The paper and the infographic series were created with support from Pfizer.

Wonder Drugs vs. Superbugs follows the release last month of ground-breaking data on the global burden of AMR in The Lancet showing that AMR itself claimed 1.27 million lives in 2019 alone and contributed to nearly 5 million deaths that year. Beyond the loss of life, the new GCOA paper explains the stakes – a threat to the foundations of our healthcare systems, and even to the very premise of human longevity – if AMR continues unaddressed at its current pace, already accelerated by widespread infection and antibiotic use in the COVID-19 pandemic.

“AMR and the impact of our lack of new antibiotics pose an urgent and growing threat to the world that could soon eclipse that of the COVID-19 pandemic,” said Mike Hodin, CEO of the Global Coalition on Aging. “But those of us who know this have not done a good job at communicating what AMR is or what it means for us, our parents, and our children. This paper aims to correct this by clearly explaining the risk from AMR and what we, collectively and individually, can do about it,” said Hodin.

Germs evolve and many will develop into superbugs capable of evading the drugs we have developed to combat them. Once-defeated diseases are reemerging, and the rise of drug-resistant infections threatens a century of medical innovation. Worldwide, drug-resistant infections, which already killed 1.27 million people each year pre-COVID, are on track to claim an estimated 10 million lives each year by 2050.

As AMR grows, people with once-treatable conditions will be at greater risk of infection and even death. Relatively common surgeries, including cesarean sections, joint replacements, and organ transplants will become deadly, and many lives will be lost due to drug-resistant infections, including sepsis. Notably, the GCOA report was released alongside Sepsis Survivor Week.

The GCOA paper aims to highlight and elucidate the challenges of this silent and growing pandemic and calls on leaders to take four steps to bring needed attention to and action on AMR:

  • Reinvent and reimagine AMR to capture public attention
  • Broaden the audience to spur advocacy for new drugs
  • Establish right-size incentives to drive the discovery and development of new drugs
  • Adapt the COVID-19 model of collaboration for medical innovation

 

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Joe Biden’s ‘Cancer Moonshot’ May be Derailed by New Policies, Including His Own

For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

Kishida and Biden Face a Similar Demographic Crisis

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.

New Report From the Global Coalition on Aging Highlights the Connection Between Adult Immunization and Economic Health in Aging APEC Region

As leaders from across the Asia-Pacific Economic Cooperation (APEC) region convene in San Francisco over the next week, a new report from the Global Coalition on Aging (GCOA) points to investments in healthy aging as a growing economic imperative amid the region’s changing demographics. According to the new report, programs that keep populations healthy, active, and productive – like adult immunization – are increasingly becoming a prerequisite for economic stability and growth.